Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?

Alessandra Fabi,Mariangela Ciccarese, Sinome Scagnoli,Michelangelo Russillo,Francesco Schettini,Giuseppe Buono, Vito Lorusso,Katia Cannita,Grazia Arpino,Simonetta Stani,Michela Palleschi, Rosalba Rossello, Giuseppina Sarobba,Agnese Fabbri,Marianna Giampaglia,Patrizia Pellegrini,Vincenzo Adamo,Francesca Morelli, Vittoria Barberi,Gianluigi Ferretti, Giovanna Catania, Simona Pisegna,Francesco Cognetti,Diana Giannarelli

Oncology（2021）

引用 1|浏览2

暂无评分

摘要

patients who were progressive on P+ET could still benefit from a subsequent ET. In patients who experienced a good efficacy from prior ET, without visceral metastatic sites, HT seems the most suitable option, when compared to CT, also in terms of safety.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要